Additionally, in a recent phase I/II clinical trial in relapsed or refractory ABC-DLBCL it was shown that 80% of patients who harbor a MYD88 together with a CD79B mutation were sensitive to the B cell receptor (BCR) signaling inhibitor ibrutinib. This evidence concerns the gene MYD88 and aneurysmal bone cyst.